Ginkgo Bioworks Holdings stock
DNANYSEGinkgo Bioworks Holdings, Inc., HealthcareISIN US37611X2099
41Score 41 out of 100, Weak
Price and trend
70 / 100
Price history
+22% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 18% above it.
Since October 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 51).
The price is 32% below its 52-week high. Largest decline in 6 years: 99% (November 2021 to September 2024).
Chart figures for advanced users
- SMA 50$10.24
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$8.64
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)51
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$5.48
- The lowest closing price of the last twelve months.
- Resistance$14.98
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Ginkgo Bioworks Holdings, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $688.89M, is number 217 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $170.16M (down 25.1% year on year) and a loss of $312.76M.
- MEQIRI Score 41 out of 100 (Weak): rank 525 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
None of our strength checks applies.
Weaknesses
- DilutionShare count up 75% since 2020.Capital allocation 18
- Volatile share priceVolatility 104% a year over the last 12 months.Stability 53
- Loss-makingLoss of $251.03M over the last 12 months.Fundamentals 17
Its standout strengths are momentum and technical analysis, while capital allocation and fundamentals hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 42 to 41.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue fell 44.2% on the twelve months before. Revenue has grown strongly since 2019, at around 21% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 81%, operating −185%, net −184%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is elevated; no interest coverage is reported.
Earnings
- Next earnings
- 25 Feb 2027in 104 days
- Last reported
- 5 Nov 2026EPS reported −$0.64 (expected −$0.68)above expectations
Analyst estimates
- Earnings per share
- −$4.36−11.4%
- Revenue
- $87.47M+2.8%
- Earnings per share
- −$4.03−19.6%
- Revenue
- $95.73M−0.3%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −9.3%2026 cash burn guidance of $125 million to $150 million reaffirmed, no revenue guidance is given.
“In terms of outlook for the full year, we are reaffirming our overall cash burn guidance for 2026, totaling $125 million to $150 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 4 insiders sold, $970,984 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Coen Steven P.Sale
19 Oct 2026, See remarks
- Shares
- 766
- Price
- $10.14
- Value
- $7,770
- Shetty Reshma P., Canton BarrySale
19 Oct 2026, 10 percent owner, officer: See remarks
- Shares
- 41,172
- Price
- $10.14
- Value
- $417,608
- Kelly Jason RSale
19 Oct 2026, See remarks
- Shares
- 45,682
- Price
- $10.14
- Value
- $463,353
Show 5 more
- Coen Steven P.Sale
5 Oct 2026, See remarks
- Shares
- 2,403
- Price
- $15.00
- Value
- $36,045
- Henry Christian OSale
15 Sept 2026, Board
- Shares
- 5,000
- Price
- $7.08
- Value
- $35,405
- Coen Steven P.Sale
24 Aug 2026, See remarks
- Shares
- 330
- Price
- $6.98
- Value
- $2,302
- Coen Steven P.Sale
17 Jul 2026, See remarks
- Shares
- 752
- Price
- $7.90
- Value
- $5,943
- Coen Steven P.Sale
22 May 2026, See remarks
- Shares
- 307
- Price
- $8.33
- Value
- $2,559
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Ginkgo Bioworks Holdings
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 41
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Prime MedicinePRME $705.56M37
- Janux TherapeuticsJANX $703.61M33
- Achieve Life SciencesACHV $697.68M41
- Nuvectis PharmaNVCT $695.69M46
- Kura OncologyKURA $682.66M27
- Design TherapeuticsDSGN $677.5M37
- ArriVent BioPharmaAVBP $676.02M29
- Bicara TherapeuticsBCAX $671.17M31
ETFs that hold Ginkgo Bioworks Holdings
Held by 10 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Artificial Intelligence UCITS ETFXMLD | 1.20% | 0.49% | €1.96B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.02% | 0.30% | €4.28B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.02% | 0.30% | €2.22B |
Show 5 more
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.01% | 0.30% | €944.34M |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.01% | 0.43% | €2.5B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.00% | 0.45% | €1.53B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.00% | 0.10% | €395.74M |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.00% | 0.25% | €175.89M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Apr 2022)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.